Phase II Study of Atezolizumab and Tiragolumab With ctDNA for HPV-positive SCC

Sponsor
M.D. Anderson Cancer Center
Study ID
NCT06762808
Phase
PHASE2
Status
Withdrawn

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Atezolizumab — DRUG
    Given by IV infusion
  • Talazoparib — DRUG
    Given by IV infusion

Study Details

A single-arm, phase II study for patients with detectable HPV CtDNA at 12 weeks or longer after completion of definitive therapy for non-metastatic, HPV+ squamous cell carcinoma.

Key Dates

Start date
May 1, 2025
Status verified
Aug 2025
Primary completion
Aug 8, 2025
Completion
Aug 8, 2025

Study Design

Enrollment
0 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Atezolizumab + Tiragolumab
    Treatment will be administered on an outpatient basis

Primary Outcome Measure

Safety and Adverse Events (AEs) [ Time Frame: Through study completion; an average of 1 year. ]

Related Studies